55-month follow-up from glow: fixed-duration ibr ven vs clb o in treatment naΓ―ve cll
Published 6 months ago β’ 82 plays β’ Length 1:35Download video MP4
Download video MP3
Similar videos
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
1:17
optimizing initial therapy in cll: time-limited, all-oral approaches
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
12:46
fixed duration treatment strategies in cll
-
0:53
the future of cll treatment
-
1:45
cancer patient story | what is chronic lymphocytic leukemia (cll)? | the patient story
-
3:14
what you need to do after your facelift surgery!
-
5:24
advanced facelift - day by day actual patient recovery in her own selfies
-
2:59
clinical trial updates and time-limited therapy in cll
-
2:51
the optimum approach to frontline treatment of cll in 2021
-
4:32
a look back & future directions for aortic surgery
-
1:28
the future of cll treatment
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
1:33
future advancements in the treatment of cll
-
1:00
insights into the future of the cll treatment landscape
-
1:19
cll treatment: a look into the future
-
1:11
making clinical decisions with patients
-
3:48
how far are we from a cure for cll?
-
1:22
the future of cll treatment and more personalized approaches
-
1:52
resonate: five-year follow-up of ibrutinib for cll
-
![cellucare π΄β
[[ new feedback!! ]]π΄cellucare review - consumer reports - is cellucare truly effective](https://i.ytimg.com/vi/f6F5ddR2FDA/mqdefault.jpg)
3:01
cellucare π΄β [[ new feedback!! ]]π΄cellucare review - consumer reports - is cellucare truly effective